Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Pomalidomide Labeled an Advance in Multiple Myeloma

December 10th 2012

The combination of pomalidomide and a steroid significantly improved outcomes for patients with MM who have exhausted other novel therapies, marking what researchers say is a notable advancement for a sizable proportion of those treated for the disease.

MLN9708 May be Alternative to Bortezomib in Multiple Myeloma

December 10th 2012

MLN9708 has shown comparable efficacy and greater convenience and tolerability than bortezomib, for patients with multiple myeloma.

Dr. Erba on Treatment-Related Mortality Rates in AML

December 9th 2012

Harry Erba, MD, PhD, professor of medicine and director, University of Alabama at Birmingham Hematologic Malignancy Program, explains the declining treatment-related mortality (TRM) rates in AML patients.

Ibrutinib Performance in CLL Patients Hailed

December 9th 2012

The novel targeted agent ibrutinib has demonstrated dramatic activity in hard-to-treat patients with CLL when used alone and in combination with rituximab.

Genes Predispose Some Anthracycline Patients to Heart Failure

December 9th 2012

Researchers have identified a genetic profile of the patients who are most likely to develop congestive heart failure after being treated with anthracyclines and then undergoing hematopoeitic stem cell transplant (HCT) for a range of blood cancers.

Dr. John Byrd Discusses Ibrutinib in CLL

December 8th 2012

John C. Byrd, MD, director of the division of hematology at The Ohio State University Comprehensive Cancer Center, discusses the new and updated results of a phase Ib/II study involving ibrutinib at the ASH Annual Meeting and Exposition.

New Data on Horizon in Several Key Areas

December 3rd 2012

Although new therapies have revolutionized the management of certain hematologic malignancies during the past 15 years, clinical trials currently under way hold the potential to yield new targeted agents and better treatment strategies.

Dr. Roboz on Improving the Standard Treatment of AML

November 30th 2012

Gail J. Roboz, MD, associate professor of medicine, director of the Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City, explains research into potential improvements to the standard treatment of AML.

In CML, Next-Generation TKIs Aim to Boost Outcomes

November 30th 2012

Researchers are continuing to investigate TKIs to help manage patients with CML who either do not respond to initial therapy or relapse after subsequent treatment.

Dr. Renier Brentjens on Genetically-Modified T Cells

November 21st 2012

Renier J. Brentjens, MD, PhD, Leukemia Service, Memorial Sloan-Kettering Cancer Center, explains the process by which his laboratory at MSKCC genetically modifies immune cells to fight cancer.

Dr. Kantarjian on the Optimal Frontline Treatment for CML

November 8th 2012

Hagop M. Kantarjian, MD, from MD Anderson Cancer Center, discusses the optimal frontline therapy for patients with chronic phase chronic myelogenous leukemia.

Switching Therapy Following Suboptimal Response in Chronic Myelogenous Leukemia

November 7th 2012

Now that several effective agents are FDA-approved for the treatment of CML, it is important to ascertain whether a treatment is working, and if not, how to respond in terms of switching treatment.

Current and Emerging Strategies for Managing Relapsed/Refractory Hodgkin Lymphoma

November 5th 2012

Transplant remains the cornerstone of treatment for relapsed/refractory Hodgkin lymphoma, but some new approaches are on the horizon and may also prove to be valid options.

Small-Molecule Inhibitors Hold Promise for Elderly CLL Patients

October 29th 2012

In early clinical trials, small-molecule inhibitors have demonstrated improvement in response rates in elderly patients with chronic lymphocytic leukemia.

FDA Approves Synribo for CML

October 26th 2012

The FDA has approved omacetaxine mepesuccinate for the treatment of adult patients with Philadelphia chromosome-positive CML who have progressed after treatment with at least two prior TKIs.

Detecting Bone Disease in Multiple Myeloma Patients

October 16th 2012

It is important for oncologists to monitor, design, and administer appropriate bone health treatments at the earliest stages for the 80% to 90% of patients with multiple myeloma who develop osteolytic bone lesions.

First-Line Dose-Dense Induction and High-Dose Chemotherapy/Autologous Stem Cell Transplant Benefits Patients With Rare Lymphomas

October 8th 2012

Dose-dense induction with high-dose chemotherapy/autologous stem-cell transplantation is reasonable for use as first-line treatment of transplantation-eligible patients with systemic peripheral T-cell lymphomas.

Lessons on Patient Care Learned at Home

September 28th 2012

This fellow shares the insights heâ€™s gained from his wife, a pediatric oncology nurse, and how they help in the care he provides.

Decitabine Outperforms Standard Treatments in Older Patients With Acute Myeloid Leukemia

September 27th 2012

Decitabine produced a higher response rate than standard therapies in older patients with newly diagnosed acute myeloid leukemia without major differences in safety.

Dr. Zelenetz Previews the 2012 ASH Annual Meeting

September 26th 2012

Andrew D. Zelenetz, MD, PhD, from Memorial Sloan-Kettering Cancer Center, previews several trials that will likely be presented at the 54th annual ASH meeting.